ライフサイエンスコーパス: infusion rate

1 for the 100-200 microu (kg body weight)(-1) infusion rates).

2 matrix calcium loads that are independent of infusion rate.

3 and usually responded to adjustments in the infusion rate.

4 aximal (240 pmol x kg(-1) x min[-1]) insulin infusion rate.

5 after 1 hr of propofol at the same previous infusion rate.

6 ol/l; P = 0.009), despite matched intralipid infusion rates.

7 n rate and was not increased at the 2 lowest infusion rates.

8 ere then compared with the known intraportal infusion rates.

9 performed in 22 infants given feedings at 2 infusion rates.

10 he brain decreases exponentially with faster infusion rates.

11 concentrations in patients receiving similar infusion rates.

12 ulation of </= 78 pg/ml, even at the highest infusion rates.

13 combined with indirect calorimetry (insulin infusion rate (1.5 mU x kg-1 x min-1)) in 12 male patien

14 were more insulin resistant (median glucose infusion rate 10.1 vs. 18.9 mg/kglean/min; P < 0.0001) a

15 h euglycemic-hyperinsulinemic clamp (insulin infusion rate = 100 mU x m(-2) x min(-1)), and a 75-g OG

16 es resulted in significantly greater glucose infusion rates (16 +/- 2 vs. 6 +/- 2 and 6 +/- 3 micro m

17 omol x kg[-1] x min[-1]) and maximal insulin infusion rate (240 micromol x kg[-1] x min[-1]).

18 ats/min after TMLR, p = 0.01) and dobutamine infusion rate (26 +/- 9 micrograms/kg body weight per mi

19 The insulin infusion rate (4 mU.kg(-1).min(-1)) was selected to matc

20 A2) were infused with intralipid at a higher infusion rate (44%) to match the arterial concentrations

21 , SIT increased insulin sensitivity (glucose infusion rate: 6.3 +/- 0.6 vs. 8.0 +/- 0.8 mg kg(1) min(

22 would be required to inject the bolus at the infusion rate = 60 min), and arterial blood was collecte

23 Elimination of VUR required a slowed infusion rate, a reduced inoculum volume (25 microliter)

24 The glucose infusion rate (adjusted for fat free mass and circulatin

25 nemic euglycemic clamping, showing a glucose infusion rate among carriers 2 times that among controls

26 greater when given at a slow than at a fast infusion rate, an effect more pronounced for albumin.

27 sitivity, as indicated by 42% higher glucose infusion rate and 90% greater muscle [(3)H]-2-deoxygluco

28 and cardiac index beginning with the lowest infusion rate and achieving maximal increases in stroke

29 GF6A required a significantly higher glucose infusion rate and demonstrated higher insulin levels dur

30 48% reduction of insulin-stimulated glucose infusion rate and glucose clearance, respectively.

31 Glucose infusion rate and leg glucose extraction during the clam

32 Glucose infusion rate and leg glucose uptake was decreased by in

33 amp studies showed a 75% decrease in glucose infusion rate and markedly reduced 2-deoxyglucose uptake

34 d from distension responses by adjusting the infusion rate and opening or closing the drainage port i

35 may be predicted by the high-dose lorazepam infusion rate and osmol gap.

36 cant correlation between high-dose lorazepam infusion rate and serum propylene glycol concentrations

37 DIO mice revealed that MTZ increased glucose infusion rate and suppressed endogenous glucose producti

38 venous bolus dose, when given, and diltiazem infusion rate and time necessary to achieve the target h

39 rate increased modestly (8%) at the maximal infusion rate and was not increased at the 2 lowest infu

40 U/kg/min) and maximal (25 mU/kg/min) insulin infusion rates and demonstrated the presence of insulin

41 TS-As expected, diazoxide suppressed glucose infusion rates and increased glucagon and epinephrine re

42 The changes in glucose infusion rates and plasma insulin levels demonstrate an

43 By tweaking fluid infusion rates and pneumatic pressures and maintaining c

44 correct flow-sheet charting, concentration, infusion rate, and dose administered, as well as patient

45 ltage, heated capillary temperature, solvent infusion rate, and solvent composition, are evaluated an

46 concentration four-fold compared to the same infusion rate at normothermia, leading to increased syst

47 were used: 1) euglycemic clamp with insulin infusion rates at 40, 120, 300, and 1,200 mU / m / min c

48 n examinations performed with contrast agent infusion rates compatible with or higher than those of h

49 In patients with HF, sitaxsentan caused an infusion rate-dependent decrease in local PVR (P<0.05 ve

50 h peak levels of dopamine were unaffected by infusion rate, dopamine levels increased more rapidly wh

51 The glucose infusion rate during a hyperinsulinemic-euglycemic clamp

52 btracting the integrated decrease in glucose infusion rate during the 4 h after glucose ingestion fro

53 btracting the integrated decrease in glucose infusion rate during the 4-h period after glucose ingest

54 glucose ingestion, the steady-state glucose infusion rate during the insulin clamp was decreased app

55 glucose ingestion, the steady-state glucose infusion rate during the insulin clamp was decreased app

56 Glucose infusion rates during hyperinsulinemic-hyperglycemic cla

57 male alphaZnT8KO mice required lower glucose infusion rates during hypoglycemic clamps and displayed

58 eady-state concentrations at even the lowest infusion rate exceeding endogenous concentrations by at

59 (-1) and maintained at the maximal tolerated infusion rate for an additional 2 hours.

60 ibody; reactions were reduced by slowing the infusion rate for later patients.

61 The infusion rate for patients receiving cisatracurium was 3

62 The starting infusion rate for subcutaneous fentanyl varied from 5 to

63 ng effect was better with a slow than a fast infusion rate for the colloids, especially albumin, but

64 Much higher infusion rates for CNP (50 microg/kg/min), which yielded

65 lication of propofol use, especially at high infusion rates for prolonged periods.

66 1.0, and 0.17 mg/min, respectively; constant infusion rates for V and I of 0.2 and 0.3 mg/min, respec

67 e, 5-min microdialysis samples (2 microl/min infusion rate) from amygdala and locus ceruleus complex

68 hip between steady state glucose and glucose infusion rate (GE[CLAMP(total)]), Rd (GE[CLAMP(uptake)])

69 , as reflected by a markedly reduced glucose infusion rate (Ginf) during the clamp (21.4 +/- 2.3 vs.

70 LPL haplotypes showed linkage to the glucose infusion rate (GINF), a direct physiologic measurement o

71 Glucose infusion rates (Ginf) decreased significantly in the Lip

72 l-NMMA injection also increased the glucose infusion rate (GIR) and decreased epinephrine secretion

73 to 32 and 49%, respectively, in the glucose infusion rate (GIR) in the hyperinsulinemic euglycemic c

74 in secretion, insulin clearance, and glucose infusion rate (GIR) needed to maintain hyperglycemia.

75 In the latter, the glucose infusion rate (GIR) required to maintain euglycemia (40.

76 ring the hyperinsulinemic clamp, the glucose infusion rate (GIR) required to maintain euglycemia and

77 ent was not paralleled by reduced HG glucose infusion rate (GIR).

78 tors explaining observed variance in glucose infusion rate (GIR).

79 d slower acquisition of steady-state glucose infusion rates (GIR) after a 5-h fast.

80 ated SU rats were insulin-resistant (glucose infusion rate [GIR] = 14.5 +/- 1.1 mg.kg(-1).min(-1)); m

81 Glucose infusion rates (GIRs) during the last 30 min of the clam

82 Glucose infusion rates (GIRs) had to be increased more after nas

83 tic glucose balance, calculated when glucose infusion rates (GIRs) were ~20 micromol kg(-1) min(-1) i

84 The same infusion rates given through 1 end hole (n=6) or in the

85 ies revealed a dramatically improved glucose infusion rate, glucose disposal rate, and hepatic glucos

86 lycemic plateaus by variable labeled glucose infusion rate; glucose effectiveness (GE) was quantified

87 Using the same infusion rate, glutamate or denatonium solutions produce

88 er minute]) and insulin sensitivity (glucose infusion rate > or = 7.50 mg/kg per minute [range, 7.52

89 The infusion rate, hub pressure, and location were documente

90 lamp study caused a reduction in the glucose infusion rate in nondiabetic rats exposed to recurrent h

91 monitors the EEG and adjusts the anesthetic infusion rate in real time to maintain the specified tar

92 Glucose infusion rate in response to insulin infusion was used t

93 increased as a function of fluid volume and infusion rate in wild-type animals, but W/W(v) animals s

94 ponses, whereas glybenclamide raised glucose infusion rates in conjunction with reduced glucagon and

95 ortex, and cerebellum were normalized to the infusion rate (in becquerels per hour).

96 e found to be dependent on plasma fatty acid infusion rates, independent of changes in plasma insulin

97 At the 0.5 mU x kg(-1) x min(-1) insulin infusion rate, leg FFA release was almost completely sup

98 s used to define insulin resistance (glucose infusion rate < or = 4.00 mg/kg of body weight per minut

99 Lower infusion rates make the studies more likely to accuratel

100 1.1%-16.4%) that improved when corrected for infusion rate (mean, 8.2%-9.9%) or for injected dose (me

101 compared with nondiabetic controls: glucose infusion rate (mg/kg FFM/min) = 6.19 +/- 0.72 vs. 12.71

102 e control subjects, CR increased the glucose infusion rate needed to maintain euglycemia during hyper

103 ion and, consequently, the exogenous glucose infusion rate needed to maintain hypoglycemia were signi

104 insulin sensitivity (i.e., GIR, the glucose infusion rates needed to maintain euglycemia during hype

105 Glucose infusion rate, nonhepatic glucose uptake, and tracer-det

106 d with insulin resistance, with mean glucose infusion rates (normal/fatty liver/NASH) of step 1, 4.5/

107 were uptitrated over 4 hours from an initial infusion rate of 0.1 microg x kg(-1) x min(-1) to a maxi

108 Use of a standard infusion rate of 0.5 mg/kg/min is safe, logical, and the

109 in a rat model of arterial thrombosis at an infusion rate of 10 micrograms/kg/min, exhibits oral bio

110 ctive fashion that 500 mL of 3% saline at an infusion rate of 100 mL per hour can be given safely.

111 With an infusion rate of 120 mL/min, cooling rates for the salin

112 /min and was achieved in 4.8 hrs with a mean infusion rate of 14.8 mg/hr.

113 was infused by a syringe pump at a constant infusion rate of 5 muL/min.

114 rostacyclin was administered at a continuous infusion rate of 5 ng/kg/min for 60 mins.

115 g in 250 mL of 5% dextrose for 45 mins at an infusion rate of 62.5 mL/hr.

116 At the highest infusion rate of acetylcholine (16 microg (100 ml tissue

117 Similarly, at the highest infusion rate of substance P (125 pg (100 ml tissue)(-1)

118 e output measurements were used to guide the infusion rate of the lactated Ringer's.

119 was increased to 75 mm Hg by increasing the infusion rate of the vasoactive agent.

120 Subsequently, the infusion rate of the vasoactive drug was reduced until a

121 fect on the systemic arterial pressure at an infusion rate of up to 24 nmol.kg-1.min-1.

122 andomly assigned and were studied at insulin infusion rates of 0, 20, 40 and 120 mU/min/m2 body surfa

123 ly suppressed glycerol appearance at insulin infusion rates of 10 mU. m(-2). min(-1).

124 , ANP failed to lower blood pressure even at infusion rates of 50 microg/kg/min.

125 tracoronary adenosine, and during increasing infusion rates of saline at room temperature through a d

126 ients had a marked depressor response to low infusion rates of trimethaphan; the response in PAF pati

127 Larger infusion rates offer no further benefits.

128 n resistance, with a 33% decrease in glucose infusion rate (P < 0.01).

129 a approximately 35% reduction in the glucose infusion rate (P < 0.05 vs. control).

130 y to insulin, evidenced by increased glucose infusion rate (P = 0.077) and significantly increased sk

131 At similar steady-state infusion rates, plasma dopamine concentrations varied ov

132 splayed a significantly higher glucose clamp infusion rate posttreatment (9.1 +/- 1.3 intensive insul

133 th hyperinsulinemic-euglycemic clamp glucose infusion rate (r = -0.28, P < 0.05).

134 Lorazepam infusion rates ranged from 0.1 to 0.33 mg.kg.hr and last

135 Cisatracurium infusion rates ranged from 6.3 to 10.5 microg/kg/min, wi

136 Y) mice, A(2B)R antagonism increased glucose infusion rate, reduced hepatic glucose production, and i

137 The glucose infusion rate required to clamp glucose at 65 mg/dl was

138 uglycemic clamp reveals an increased glucose infusion rate required to maintain euglycemia and showed

139 inavir treatment acutely reduced the glucose infusion rate required to maintain euglycemia by 18 and

140 th a 36% reduction (P < 0.05) in the glucose infusion rate required to maintain euglycemia during hyp

141 s reflected by a 25% increase in the glucose infusion rate required to maintain euglycemia during the

142 ipid and lactate infusions decreased glucose infusion rates required to clamp plasma glucose by appro

143 At the lower dose, the exogenous glucose infusion rates required to maintain euglycemia during st

144 The glucose infusion rates required to maintain identical glucose le

145 The glucose infusion rates required to maintain target plasma glucos

146 ximately 30%, as indicated by portal glucose infusion rate (saline 15.9 +/- 1.6 vs. exenatide 20.4 +/

147 ze citrate and will require calcium chloride infusion rates significantly above normal.

148 suppressed, whereas muscimol raised glucose infusion rates significantly compared with controls.

149 In dogs with infusion rates similar to insulin itself, NN304 exhibits

150 n with the 1.0 mU x kg(-1) x min(-1) insulin infusion rate, splanchnic FFA release decreased by only

151 +RH group required a 1.7-fold higher glucose infusion rate than those in the STZ group, consistent wi

152 artery (SPDa) of STZ-administered rats at an infusion rate that did not alter systemic venous glucose

153 ntravenous infusions of rhRLX over 5 h at an infusion rate that was chosen to sustain serum concentra

154 At the highest infusion rates, they exhibited diuresis, dehydration, an

155 At higher infusion rates, they were unable to process further gluc

156 he was ameliorated at 5 mg by prolonging the infusion rate to 20 minutes, but dose-limiting headache

157 (EEG) and manually titrating the anesthetic infusion rate to maintain a specified level of burst sup

158 ch Sur2(-/-) mice required a greater glucose infusion rate to maintain a target blood glucose level.

159 Lastly, the glucose infusion rate to maintain the desired hypoglycemia was s

160 /-) and Adipo(+/+) mice have similar glucose infusion rates to maintain a similar serum glucose.

161 icker animals required higher norepinephrine infusion rates to maintain blood pressure (and higher FI

162 stablish maximum tolerated dose (the highest infusion rate tolerated by at least eight participants)

163 At the insulin infusion rate used, the magnitude of this defect was com

164 The total GLC infusion rate was 14% greater in dogs infused with GLC t

165 Mean infusion rate was 2.8 mL/sec (range, 1-5 mL/sec).

166 Their glucose infusion rate was 30% higher than that of the WT mice in

167 The glucose infusion rate was 44.2 +/- 3.5% higher (P < 0.01) during

168 The median peak infusion rate was 67 microg/kg/min (range, 19-200).

169 The propofol infusion rate was adjusted and repeat loading doses were

170 Indeed, the insulin-stimulated glucose infusion rate was decreased by 12-31%; suppression of he

171 Glucose infusion rate was identical between groups before treatm

172 The glucose infusion rate was increased more than 30% in the hyperin

173 ructose on glucose kinetics, average glucose infusion rate was markedly reduced in the fructose infus

174 plication in lean subjects, a higher glucose infusion rate was necessary to maintain euglycemia compa

175 eeks after lesioning showed that the glucose infusion rate was significantly lower in SCN lesioned mi

176 2 h of insulin infusion, whole-body glucose infusion rate was significantly lower in the obese versu

177 The standard infusion rate was then modified to 30 minutes for all be

178 The steady-state glucose infusion rate was threefold higher in the MR group and c

179 om steady-state ICP at different ventricular infusion rates, was not affected by AQP1 deletion.

180 azepam received and mean high-dose lorazepam infusion rate were 8.1 mg/kg (range, 5.1-11.7) and 0.16

181 The 72-hour average insulin infusion rates were 3.37 +/- 0.61 and 4.57 +/- 1.18 U/hr

182 Initial boluses and infusion rates were as follows: lorazepam 0.05 mg/kg, th

183 Infusion rates were determined by caregivers and ranged

184 noted in men than in women, whereas glucose infusion rates were higher in women.

185 ring exercise were also reduced, and glucose infusion rates were increased following prior euglycemia

186 istration of bicuculline methiodide, glucose infusion rates were significantly suppressed, whereas mu

187 al glucose levels during the similar insulin infusion rates were substantially lower in diabetic Indi

188 effects of these identical AICAR and insulin infusion rates were then examined in the obese Zucker ra

189 ated by C-peptide deconvolution) and insulin infusion rates were used as inputs to a new two-compartm

190 Consecutive 5-min samples (2 microl/min infusion rate) were obtained from left amygdala and ipsi

191 stance with significant increases in glucose infusion rates, whole-body glucose turnover, and skeleta

192 he lower intrinsic activity allowed a higher infusion rate with M5, which induced the most rapid and

193 e but not at 140 mug/kg per minute adenosine infusion rate, with mean difference (95% confidence inte

194 Thus, we hypothesized that glucose infusion rate would be augmented and neuro-hormonal coun